Abstract
Abstract
Xanthohomul (XN), a naturally prenylated flavonoid, is extracted from hops (Humulus lupulus L.; Cannabaceae). XN treated NG108-15 cells significantly decreased cell viability through increased ROS and arrested the cell cycle at G1/S phase. Notably, XN treatment did not induce apoptotic responses. Further research revealed XN-treatment increased reactive oxygen species (ROS) levels which was alleviated by N-acetyl-L-cysteine (NAC). Moreover, XN triggered the phosphorylation of the estrogen-regulated kinase (ERK1/2) and p38 mitogen activated protein kinase (MAPK). Intriguingly, our observations indicated that only ERK inhibitor could partly relieve XN-induced G1/S cycle arrest and proliferation inhibition. Hence, XN emerges as a prospective candidate for an anti-neurotumor pharmaceutical agent.
Publisher
Research Square Platform LLC
Reference31 articles.
1. Louis, D. N.et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.Neuro Oncol. 23(8), 1231–1251 (2021).
2. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas;Weller M;Lancet Oncol,2017
3. Miller, J. J.et al. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Cancer. 123(23), 4535–4546 (2017).
4. Emerging role of plumbagin: Cytotoxic potential and pharmaceutical relevance towards cancer therapy;Tripathi SK;Food Chem Toxicol,2019
5. Xanthohumol for Human Malignancies: Chemistry, Pharmacokinetics and Molecular Targets;Harish V;Int J Mol Sci.,2021